Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Short LLY ETF

8.57
0.0000
Volume:- -
Turnover:- -
Market Cap:1.54M
PE:- -
High:8.57
Open:8.57
Low:8.57
Close:8.57
52wk High:21.15
52wk Low:7.63
Shares:180.00K
Float Shares:180.00K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

BMO Capital Remains a Buy on Eli Lilly & Co (LLY)

TIPRANKS
·
Mar 20

Novo Nordisk Patent Expiry Opens Door to Cheaper Weight-Loss Drugs in India

Reuters
·
Mar 20

Market Chatter: Eli Lilly Alzheimer's Drug to be Reconsidered by UK Health Regulator

MT Newswires Live
·
Mar 20

Eli Lilly Wins Appeal for Alzheimer's Drug, Prompting NHS Review of Coverage

Stock News
·
Mar 20

Health Rounds: Diabetes patients who stop GLP-1 drugs increase their heart risks

Reuters
·
Mar 20

Sanofi SA Stock (SNY) Moved Up by 3.07% on Mar 19: Key Drivers Unveiled

TradingKey
·
Mar 20

A high dose of Wegovy helped people lose 21% of their weight. It was just approved.

Dow Jones
·
Mar 20

Eli Lilly Advances EMERALD-3: A New Oral Bet in Ulcerative Colitis

TIPRANKS
·
Mar 20

US FDA approves higher dose of Novo's Wegovy under new fast-track review program

Reuters
·
Mar 20

Eli Lilly data compare favorably to Mounjaro, Ozempic, says Deutsche Bank

TIPRANKS
·
Mar 19

Eli Lilly retatrutide results ‘favorable,’ but similar to Mounjaro, says Truist

TIPRANKS
·
Mar 19

Top Midday Stories: Qatar Loses 17% of LNG From Iranian Attacks; Micron Shares Fall Despite Strong Q2 Earnings

MT Newswires Live
·
Mar 19

Eli Lilly Stock (LLY) Rises. The Pharma Giant Has Reported Some Very Good News

TIPRANKS
·
Mar 19

Eli Lilly's 'Triple Agonist' Is More Than Just a Weight-Loss Drug. This Trial Proves It. -- Barrons.com

Dow Jones
·
Mar 19

Lilly's Retatrutide Slashes Both Weight Loss and Blood Sugar Levels in Landmark Study -- Update

Dow Jones
·
Mar 19

Lilly Phase 3 TRANSCEND-T2D-1 trial shows retatrutide cuts A1C up to 2% and weight 16.8%

Reuters
·
Mar 19

Lilly's Triple Agonist, Retatrutide, Demonstrated Significant Reductions in a1c and Weight in First Phase 3 Trial for Treatment of Type 2 Diabetes

THOMSON REUTERS
·
Mar 19

Eli Lilly: Retatrutide Showed Significant Reductions in a1c & Weight in First Phase 3 Trial for Type 2 Diabetes Treatment

THOMSON REUTERS
·
Mar 19

BRIEF-Eli Lilly's Retatrutide Showed Significant Reductions In A1C & Weight In TRANSCEND-T2D-1 Trial

Reuters
·
Mar 19

Eli Lilly: Participants Taking Retatrutide 12 Mg Lost Average of 36.6 Lbs

THOMSON REUTERS
·
Mar 19